6 results about "Bladder dysfunctions" patented technology

This invention belongs to the field of biomedical technology, specifically relating to the application of plasma exosome biomarkers in the diagnosis and early warning of diabetic bladder dysfunction. This invention pioneered the use of 4D-DIA proteomics technology to conduct a comprehensive differential analysis of plasma exosome proteins from patients with diabetic bladder dysfunction (DBD). It successfully identified protein components with significantly different expression levels in the plasma exosomes of DBD patients, demonstrating significant value as potential diagnostic biomarkers. This invention is the first to propose that the detection of a four-protein combination in plasma exosomes (FCGR3B+THBS1+HLA-F+ATP5PB) can serve as a biomarker for diabetic bladder dysfunction (DBD) and also as an early warning indicator for the disease. This protein combination achieved an overall accuracy of 83.3% in identifying DBD.

1. The name of the design product: intermittent urinary catheter (pen type). 2. The use of the design product: for helping people who cannot urinate independently or have bladder dysfunction to regularly empty their bladder. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention discloses a double-target inhibitor aiming at PIEZO1 and NLRP3 and application of the double-target inhibitor in bladder dysfunction after pelvic tumor operation, based on the pathological mechanism that PIEZO1 is abnormally activated due to postoperative mechanical stimulation, Ca < 2 + > influx increase is caused, and NLRP3 inflammasome is further activated, PIEZO1 inhibiting polypeptide GsMTx4 and NLRP3 small-molecule inhibitor MCC950 are compounded according to a certain mass ratio, and the PIEZO1 inhibiting polypeptide GsMTx4 and NLRP3 small-molecule inhibitor MCC950 are compounded according to a certain mass ratio. A temperature-sensitive hydrogel sustained release preparation capable of being locally injected into the bladder is constructed, and dual-channel synergistic inhibition is achieved; animal experiments show that the composition can significantly reduce the expression level of IL-1beta, inhibit the peak amplitude of Ca < 2 + >, reduce the inflammation score and fibrosis area proportion, improve the residual urine volume and bladder capacity, and reduce the system exposure level and the risk of abnormal liver and kidney functions; the technical scheme has a clear mechanism basis and good safety, and is suitable for local intervention of postoperative bladder dysfunction.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, preparation method, pharmaceutical formulation, and application for treating cerebellar ataxia syndrome. The composition comprises the following components: Rehmannia glutinosa (raw and processed), Cistanche deserticola, Morinda officinalis, Cornus officinalis, Dendrobium nobile, Curculigo orchioides, Panax ginseng, Ophiopogon japonicus, Polygala tenuifolia, Acorus tatarinowii, Angelica dahurica, Poria cocos, Schisandra chinensis, Citrus reticulata peel, and Amomum villosum. The preparation method involves first soaking Rehmannia glutinosa (raw and processed) to obtain mixture A; then mixing the remaining ingredients and soaking them in water to obtain mixture B; finally, combining mixture A and mixture B, and decocting to obtain the final product. This traditional Chinese medicine formula can treat cerebellar ataxia syndrome, improving the main symptoms of ataxia such as gait instability, balance disorders, and dysarthria; it also helps to resolve turbidity and improve secondary symptoms such as bowel and bladder dysfunction, sleep disorders, and mental disorders, promoting patient compliance, slowing and stabilizing disease progression, and improving patients' quality of life.

The invention provides a closed-loop diagnosis and treatment method for bladder dysfunction, and relates to the technical field of biomedical monitoring and treatment. Comprising the following steps: acquiring a signal related to bladder filling through a non-invasive bladder volume measuring device, and analyzing the signal in real time to estimate the bladder volume; subsequently, the measuring device compares the estimated volume with a preset capacity threshold value and generates a trigger signal for activating an external excitation source when the volume reaches or exceeds the threshold value. The external excitation source outputs mechanical energy after receiving the trigger signal, and the mechanical energy is transmitted to the wireless nerve stimulator in the body in a wireless mode; and the stimulator converts the received mechanical energy into electric energy, and the electric energy is processed by the energy management circuit to generate an electric stimulation signal for regulating and controlling neural activity, so that the adjustment of the bladder function is realized. The defects that in a traditional diagnosis and treatment scheme, monitoring continuity is poor, intervention depends on professionals, individualized regulation and control cannot be achieved, and a closed-loop control mechanism is lacked are effectively overcome.

The present invention relates to the treatment of endometriosis using an anti-Netrin-1 antibody or an antigen-binding fragment thereof, and to such an antibody or fragment thereof for use in treating endometriosis. The treatment includes reduction of endometriotic lesions, particularly uterine and / or uterine horn endometriotic lesions. The treatment further includes relief of chronic pelvic pain or vaginal hyperalgesia. This may also include reduction of colorectal hyperalgesia developed in endometriosis, improvement of bladder dysfunction developed in endometriosis, reduction of increased skin sensitivity to heat and / or mechanical stimuli developed in endometriosis, and improvement of overall health status altered by endometriosis.